Breaking
Strawberry Moon in Capricorn Demands You Face Your Deepest Fears AI Safety Playbook Gets Major Overhaul as Companies Brace for Frontier Models The Great Fact-Check Collapse: Who Polices AI's Truth Problem? The Bedrock Nobody Thinks About Until It's Gone How Trump's Ascent Cleared Space for the DSA's Rise in Democratic Ranks Strawberry Moon in Capricorn Demands You Face Your Deepest Fears AI Safety Playbook Gets Major Overhaul as Companies Brace for Frontier Models The Great Fact-Check Collapse: Who Polices AI's Truth Problem? The Bedrock Nobody Thinks About Until It's Gone How Trump's Ascent Cleared Space for the DSA's Rise in Democratic Ranks
Health

Vitamin B12 variant breaks through brain's defenses to attack aggressive tumors

Jessica Williams 0 comments 8 min read
Vitamin B12 variant breaks through brain's defenses to attack aggressive tumors

Researchers have discovered that a modified form of vitamin B12 can penetrate one of the body's most formidable barriers and accumulate directly in deadly brain cancer tissue, potentially offering a new strategy to overcome treatment resistance in glioblastoma.

The compound, called nitrosylcobalamin, is a B12 derivative engineered to release nitric oxide. In a pilot study published in Oncoscience, investigators led by Joseph A. Bauer of the Cleveland Clinic Foundation Taussig Cancer Center found that the molecule successfully crossed the blood-brain barrier, a protective structure that has long thwarted efforts to deliver drugs to brain tumors.

Glioblastoma multiforme represents one of the most lethal brain cancers. Median survival after diagnosis hovers below 15 months, even with surgery, radiation, and chemotherapy. The blood-brain barrier is largely to blame, blocking the passage of most therapeutic agents before they can reach malignant tissue.

In rat models with glioblastoma tumors, nitrosylcobalamin demonstrated the ability to cross into the brain and selectively accumulate within tumor cells. The drug remained active for extended periods, with nitrate levels persisting in tumor tissue at least 24 hours after administration, while concentrations in healthy tissue declined rapidly. This pattern suggests the compound becomes trapped inside tumors, delivering its payload directly where it's needed.

The researchers tested nitrosylcobalamin against standard glioblastoma treatments in human cancer cell lines. When combined with either TRAIL (a protein that triggers cell death) or temozolomide (a chemotherapy drug), the vitamin B12 variant produced dramatically greater tumor suppression than any single therapy alone. The synergistic effect held across multiple dose ranges.

Nitric oxide delivery may help unlock a secondary advantage. Previous research shows that nitric oxide can trigger apoptosis through caspase-8 activation, suppress pro-survival signaling pathways, and enhance the effectiveness of TRAIL receptors. These mechanisms could help overcome tumors that have developed resistance to conventional chemotherapy.

Bauer's team stressed that the findings come from early-stage translational research. Before clinical trials could begin, additional studies must validate the approach in more complex tumor models, optimize dosing schedules, monitor nitric oxide activity over longer periods, and test the strategy in other central nervous system cancers.

The results suggest a compound that checks multiple boxes: it navigates the brain's protective barrier, homes in on malignant cells, and amplifies the killing power of existing drugs. If these properties hold up in further testing, nitrosylcobalamin could represent a meaningful advance against a cancer that has long resisted treatment.

Author Jessica Williams: "A B12 variant that actually makes it past the blood-brain barrier and boosts existing drugs is exactly what glioblastoma research has been waiting for, though it's still miles away from the clinic."

Comments